Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
25 participants
INTERVENTIONAL
2013-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Safety Study of Zileuton Injection in Patients With Asthma
NCT00299065
PF-04191834 Single Dose Bronchodilatory Study In Asthma.
NCT00723021
Assessment of PFT, Safety, and PK of Zileuton Injection in Asthma Patients
NCT00534625
Zileuton and Exhaled Nitric Oxide in Asthmatics
NCT00575861
Zileuton CR vs Placebo in Poorly Controlled Asthma Patients on Moderate Dose ICS
NCT00486343
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Zileuton extended release
Oral, 1200 mg (2 x 600 mg tablets)
Zileuton extended release
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Zileuton extended release
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* FEV1 of 50-85% predicted
* Reversible airway obstruction
Exclusion Criteria
* Liver function tests greater than upper limit of normal
18 Years
55 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Cornerstone Therapeutics Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Northeast Medical Research Associates
North Dartmouth, Massachusetts, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CRTX 082-04-01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.